DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Claims 1-13 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected groups, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/14/2026.
Applicant’s election without traverse of Group III in the reply filed on 08/14/2026 is acknowledged.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 14-21 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by DeHennis (USPN 20150182115-Cited by the Applicant).
Regarding claim 14, DeHennis discloses a method for detecting glucose in a patient comprising: administering an indicator compound to the patient, the indicator compound ([0039], [0042], [0069]) comprising: a luminescent protein domain ([0039], [0042], [0069]); and a glucose binding protein domain ([0039], [0042], [0069]); wherein the indicator compound is configured to bind glucose via the glucose binding protein domain; wherein the indicator compound is configured to undergo a conformational change from a first conformation to a second conformation when glucose is bound by the glucose binding protein domain ([0039], [0042], [0069]); wherein, when in the second conformation, the indicator compound is configured to receive an excitation wavelength and to emit a luminescent signal ([0039], [0042], [0069]); wherein a contiguous 100 amino acid portion of the glucose binding protein domain shares 80% to 100% identity, homology, or similarity to a contiguous 100 amino acid portion of one of SEQ ID NOs: 2, 15, 122-221, or 824-1746 ([0039], [0042], [0069]).
Regarding claim 15, quantifying a glucose level in the patient based on a change in luminescence of the indicator compound ([0039], [0042], [0069]).
Regarding claim 16, the indicator compound is administered to the patient using a cell ([0039], [0042], [0069]).
Regarding claim 17, the cell is autologous to the patient ([0039], [0042], [0069]).
Regarding claim 18, the cell comprises DNA having a region that encodes the indicator compound ([0039], [0042], [0069]).
Regarding claim 19, the cell is part of a skin graft received by the patient ([0039], [0042], [0069]).
Regarding claim 20, the cell is a keratinocyte, melanocyte, Langerhans cell, Merkel cell, immune cell, macrophage, epithelial cell, or red blood cell ([0039], [0042], [0069]).
Regarding claim 21, illuminating the indicator compound with light having a first maximum wavelength and detecting an emission of light at a second maximum wavelength ([0039], [0042], [0069]).
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARJAN FARDANESH whose telephone number is (571)270-5508. The examiner can normally be reached Monday-Friday 9:00-17:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jacqueline Cheng can be reached at (571)272-5596. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/MARJAN FARDANESH/Primary Examiner, Art Unit 3791
Prosecution Insights